OKYO Pharma Limited
OKYO
$2.42
$0.052.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -35.55% | -40.11% | -44.35% | -19.24% | 9.12% |
| Gross Profit | 35.55% | 40.11% | 44.35% | 19.24% | -9.12% |
| SG&A Expenses | -- | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.97% | -45.79% | -36.99% | -11.50% | 18.93% |
| Operating Income | 54.97% | 45.79% | 36.99% | 11.50% | -18.93% |
| Income Before Tax | 52.57% | 39.59% | 26.40% | 2.42% | -25.97% |
| Income Tax Expenses | -14,670.54% | -5,198.92% | -2,193.77% | -2,592.81% | 283.61% |
| Earnings from Continuing Operations | 72.03% | 53.95% | 35.62% | 7.51% | -26.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.03% | 53.95% | 35.62% | 7.51% | -26.25% |
| EBIT | 54.97% | 45.79% | 36.99% | 11.50% | -18.93% |
| EBITDA | 54.98% | 45.79% | 36.99% | 11.49% | -18.94% |
| EPS Basic | 78.76% | 64.78% | 52.78% | 28.54% | 1.76% |
| Normalized Basic EPS | 64.51% | 54.61% | 46.10% | 25.04% | 2.12% |
| EPS Diluted | 78.76% | 64.78% | 52.78% | 28.54% | 1.76% |
| Normalized Diluted EPS | 64.51% | 54.61% | 46.10% | 25.04% | 2.12% |
| Average Basic Shares Outstanding | 34.57% | 35.66% | 36.97% | 34.52% | 31.84% |
| Average Diluted Shares Outstanding | 34.57% | 35.66% | 36.97% | 34.52% | 31.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |